For US Healthcare Professionals Only
Congress Materials
FILTER
FILTER
Achieving Increasingly Stringent Clinical Disease Control Criteria is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controll
Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomize
Oral Presentation American College of Rheumatology (ACR), 2022
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Association of DLQI 0/1 with relative PASI improvements in subgroups of patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials (CIMPASI-1, CIMPASI-2, and CIMPACT)
Bimekizumab comparative efficacy in psoriasis: Number needed to treat analyses of phase 3/3b trial data
Bimekizumab comparative efficacy in psoriasis: Number needed to treat analyses of phase 3/3b trial data
Bimekizumab comparative efficacy in psoriasis: Number needed to treat analyses of phase 3/3b trial data
Bimekizumab early responses in patients with plaque psoriasis: Results from the multicenter, randomized, double-blinded phase 3b BE RADIANT trial
Poster DERM 2022 NP/PA CME, 2022
Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
Bimekizumab early treatment response translates into cumulative benefits in health-related quality of life in patients with moderate to severe plaque psoriasis: Pooled results from three multicenter, randomized, double-blinded phase 3 trials
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis who switched from secukinumab: Results from the open-label extension period of the BE RADIANT phase 3b trial
Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomised controlled trial and the BE BRIGHT open-label extension
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Bimekizumab efficacy and safety through two years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Bimekizumab efficacy and safety through two years in patients with moderate to severe plaque psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Bimekizumab efficacy in high-impact areas for patients with moderate to severe plaque psoriasis: Pooled results through two years from the BE SURE and BE RADIANT phase 3 trials
Bimekizumab efficacy in subgroups defined by prior systemic treatment in patients with moderate to severe plaque psoriasis
Bimekizumab efficacy over two years in patients with moderate to severe plaque psoriasis with scalp and nail involvement who switched from adalimumab, ustekinumab, or secukinumab: Results from the BE SURE, BE VIVID, BE BRIGHT, and BE RADIANT phase 3/3b tr
Bimekizumab efficacy through 96 weeks in patients with moderate to severe plaque psoriasis: Patient-reported outcomes from the BE RADIANT phase 3b trial
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
Bimekizumab Improves Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies
Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo-Controlled Study
Oral Presentation American College of Rheumatology (ACR), 2022
Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy and Safety from a Phase 3, Multicenter, Randomized, Placebo-Controlled Study
Oral Presentation European Congress of Rheumatology (EULAR), 2022
Bimekizumab in bDMARD-naïve patients with psoriatic arthritis: 24-week efficacy & safety from BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study
Oral Presentation European Congress of Rheumatology (EULAR), 2022
Bimekizumab in patients with active ankylosing spondylitis: 24-week efficacy & safety from BE MOBILE 2, a phase 3, multicentre, randomised, placebo‑controlled study
Bimekizumab in patients with active non-radiographic axial spondyloarthritis and active ankylosing spondylitis: 24-week efficacy and safety from the BE MOBILE phase 3 studies
Bimekizumab in patients with active non-radiographic axial spondyloarthritis: 24-week efficacy & safety from BE MOBILE 1, a phase 3, multicentre, randomised, placebo-controlled study
Oral Presentation European Congress of Rheumatology (EULAR), 2022
Bimekizumab in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: 16-week efficacy and safety from BE COMPLETE, a phase 3, multicentre, randomised, placebo-controlled study
Poster DERM 2022 NP/PA CME, 2022
Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials
Poster RheumNow Live! (RNL), 2022
Bimekizumab in patients with psoriatic arthritis: 3-year results for overall and tumor necrosis factor inhibitor (TNFi)-naïve populations from a phase 2b open-label extension study
Poster DERM 2022 NP/PA CME, 2022
Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials
Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials
Bimekizumab long-term safety and efficacy in patients with ankylosing spondylitis: Interim results after 3 years of treatment in an ongoing phase 2b study
Bimekizumab Maintains Improvements in Efficacy Endpoints and has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open- label extension trial
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial
Bimekizumab response maintenance in high-impact areas in patients with moderate to severe plaque psoriasis: Pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials
Bimekizumab response maintenance in high-impact areas in patients with moderate to severe plaque psoriasis: Pooled results through 96 weeks of the BE SURE, BE READY, and BE RADIANT phase 3/3b trials
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials
Bimekizumab shows sustained and meaningful long-term improvements in health-related quality of life in ankylosing spondylitis: interim results after 3 years of treatment in an ongoing phase 2b study
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Poster DERM 2022 NP/PA CME, 2022
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Oral Presentation American College of Rheumatology (ACR), 2022
Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
Oral Presentation American College of Rheumatology (ACR), 2022
Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Bimekizumab treatment response is maintained up to 3 years in patients with psoriatic arthritis: responder analyses from BE ACTIVE, a phase 2b dose-ranging study, and its open-label extension
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
Poster DERM 2022 NP/PA CME, 2022
Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
Poster Maui Derm NP + PA Fall, 2022
Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
Bimekizumab versus secukinumab in plaque psoriasis: Cumulative clinical and health‑related quality of life benefit through 2 years of the BE RADIANT phase 3b trial and open‑label extension
Bimekizumab versus secukinumab in plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) responses accompanying achievement of complete skin clearance in the phase 3b BE RADIANT trial
Bimekizumab versus secukinumab in plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) responses accompanying achievement of complete skin clearance in the phase 3b BE RADIANT trial
Bimekizumab versus secukinumab in plaque psoriasis: Psoriasis Symptoms and Impacts Measurement (P-SIM) responses accommpanying achievement of complete skin clearance in the phase 3b BE RADIANT trial
Bimekizumab versus secukinumab in plaque psoriasis: Reduction in body surface area affected by psoriasis translates into benefits in patient-perceived itching, skin pain, and scaling and health-related quality of life in the BE RADIANT phase 3b trial
Both IL-17RA and IL-17RC receptor complexes are required for IL-17A- and IL-17F-driven inflammation
Both IL-17RA and IL-17RC receptor complexes are required for IL-17A- and IL-17F-driven inflammation
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis and Implications for Recruitment in Clinical Studies
Complete skin clearance for patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and health-related quality of life
Complete skin clearance for patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and health-related quality of life
Complete skin clearance for patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and health-related quality of life
Complete skin clearance for patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and health-related quality of life
Efficacy and safety of bimekizumab in bDMARD-naïve patients with psoriatic arthritis: 24-week results from BE OPTIMAL, a phase 3, multicentre, randomised, placebo-controlled, active reference study
Efficacy and safety of bimekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: 16-week results from BE COMPLETE, a phase 3, randomised, double-blind placebo-controlled study
Poster Skin of Color (SOC), 2022
Efficacy of bimekizumab in patients with psoriasis and skin of color: Pooled data from four multicenter, double-blind, randomized phase 3 trials
Fatigue in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from the CIMPACT phase 3 trial
Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Active Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status
Long-term safety and efficacy of certolizumab pegol in patients with active non‑radiographic axial spondyloarthritis: 3-year results from a phase 3 multicenter study
Poster DERM 2022 NP/PA CME, 2022
Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials
Mean percent PASI improvement with bimekizumab in patients with moderate to severe plaque psoriasis: Pooled results from four phase 3/3b trials
Number needed to treat among therapies for patients with moderate to severe plaque psoriasis: Clinical perspective of results from a network meta-analysis
Poster Skin of Color (SOC), 2022
Patient-reported quality of life in patients with psoriasis with skin of color: Pooled data from four multicenter, double-blind, randomized phase 3 trials
Single-cell sequencing of freshly isolated cells from lesional and peri-lesional skin to explore cellular origins of IL-17 isoforms in psoriasis
Single-cell sequencing of freshly isolated cells from lesional and peri-lesional skin to explore cellular origins of IL-17 isoforms in psoriasis
Stable plasma concentration of certolizumab pegol is associated with clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2